BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

...average cost per year for a patient to be $96,000. Fintepla is a derivative of amphetamine...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

...review additional data for the candidate, an oral solution of low-dose fenfluramine, a derivative of amphetamine...
BioCentury | Feb 8, 2020
Product Development

Zogenix’s Fintepla underwhelms in Phase III for rare epilepsy as data fall short of GW’s Epidiolex

...full year of sales. Fintepla is an oral solution of low-dose fenfluramine, a derivative of amphetamine...
BioCentury | Nov 26, 2019
Company News

Priority Review roundup: Roche-PTC, Intercept, Zogenix

...seizures associated with Dravet syndrome was granted Priority Review. The oral low-dose solution of the amphetamine...
BioCentury | Apr 8, 2019
Company News

Zogenix gets refusal-to-file letter for Dravet syndrome therapy

...associated with Dravet syndrome. Fintepla is an oral solution of low-dose fenfluramine, a derivative of amphetamine...
BioCentury | Aug 10, 2018
Financial News

Zogenix, Progenics raise follow-ons

...treat Dravet syndrome. The therapy is an oral solution of low-dose fenfluramine, a derivative of amphetamine...
BioCentury | Aug 8, 2018
Financial News

Zogenix, Progenics raise follow-ons

...treat Dravet syndrome. The therapy is an oral solution of low-dose fenfluramine, a derivative of amphetamine...
BioCentury | Jul 13, 2018
Clinical News

Zogenix to advance regulatory plans on second Phase III win

...for Dravet Syndrome" ). ZX008 is an oral solution of low-dose fenfluramine, a derivative of amphetamine...
...ZX008 Business: Neurology Molecular target: NA Description: Oral solution of low-dose fenfluramine, a derivative of amphetamine...
BioCentury | Jul 12, 2018
Clinical News

Zogenix market cap grows with second Phase III win

...Dravet Syndrome Candidate" ). ZX008 is an oral solution of low-dose fenfluramine, a derivative of amphetamine...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

...that is expected to face generic competition in 2022-23. Mydayis, an extended-release formulation of mixed amphetamine...
Items per page:
1 - 10 of 311